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Abstract
Background. Compared with Caucasians, African Americans have lower heart rate variability (HRV) in the high-frequency 
domain, but there are no studies in Blacks born and living in Africa. Methods. in the newer versus older Antihypertensive 
agents in African Hypertensive patients trial (nCT01030458), patients (30–69 years) with uncomplicated hypertension 
(140–179/90–109 mmHg) were randomized to single-pill combinations of bisoprolol/hydrochlorothiazide (R) or amlodipine/
valsartan (E). 72 R and 84 E patients underwent 5-min ECg recordings at randomization and 8, 16 and 24 weeks. HRV was 
determined by fast Fourier transform and autoregressive modelling. Results. Heart rate decreased by 9.5 beats/min in R patients 
with no change in E patients ( 2.2 beats/min). R patients had reduced total ( 0.13 ms²; p  0.0038) and low-frequency 
power ( 3.6 nu; p  0.057), higher high-frequency ( 3.3 nu; p  0.050) and a reduced low- to high-frequency ratio ( 0.08; 
p  0.040). with adjustment for heart rate, these differences disappeared, except for the reduced low-frequency power in the 
R group ( 4.67 nu; p  0.02). Analyses confined to 39 R and 47 E patients with HRV measurements at all visits or based 
on autoregressive modelling were confirmatory. Conclusion. in native Black African patients, antihypertensive drugs modulate 
HRV, an index of autonomous nervous tone. However, these effects were mediated by changes in heart rate except for low-
frequency variability, which was reduced on beta blockade independent of heart rate.
Key Words:  Antihypertensive drugs, Blacks, heart rate variability, randomized clinical trial, sub-Saharan Africa
Blood Pressure, 2013; Early online: 1–7
iSSn 0803-7051 print/iSSn 1651-1999 online © 2013 Scandinavian Foundation for Cardiovascular Research
Doi: 10.3109/08037051.2013.836810
Introduction
The autonomic nervous system plays a role in the 
pathogenesis of hypertension. increased sympathetic 
activity or a decreased parasympathetic activity 
contribute to the development and maintenance of 
high blood pressure (1). measurement of heart rate 
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variability (HRV) in the frequency domain provides 
information on how the autonomous nervous sys-
tem controls the cardiovascular system (2). indeed, 
the high- and low-frequency components of HRV 
respectively reflect the activity of the parasympa-
thetic and sympathetic nervous system. The low- to 
high-frequency ratio is a measure of sympatho-vagal 
balance (3,4).
in subjects at risk of hypertension and in hyper-
tensive patients, the high-frequency component 
of HRV is generally reduced (5). Reduced HRV 
predicts all-cause mortality (6) and cardiac events 
(7). moreover, compared with Caucasians, African 
Americans have an increased prevalence of hyper-
tension and reduced HRV (8–14). Changes in sym-
pathetic modulation of the cardiovascular system 
might therefore be a risk factor for cardiovascular 
complications (1,6,7,15,16), which might be 
 reversible by blood-pressure lowering treatment. 
However, to our knowledge, no study addressed the 
role of the autonomic nervous system in cardiovas-
cular regulation in Black hypertensive patients born 
and living in Africa. we addressed this issue in the 
newer versus older Antihypertensive Agents in 
African Hypertensive patients trial (noAAH; 
nCT01030458), of which the protocol (17) and 
main results (18) were reported elsewhere. The cur-
rent article reports on changes in HRV on random-
ized treatment with older and newer drugs in native 
African hypertensive patients.
Methods
The noAAH trial was an open, randomized, inves-
tigator-led multicentre study complying with the 
guidelines for good clinical practice (19). Six centres 
located in Cameroon (n  2), gabon (n  1), nigeria 
(n  2) and Senegal (n  1) enrolled patients. The 
sponsor (Hypertension Unit, University of Kinshasa 
Hospital, Democratic Republic of Congo) and all 
participating centres obtained ethical clearance from 
their local institutional review boards and/or national 
regulatory authorities. patients provided written or 
witnessed informed consent at screening.
As outlined in detail in the published protocol 
(17), treatment-naïve or previously treated patients 
of either sex, aged 30–69 years with uncomplicated 
grade-1 or grade-2 hypertension and a maximum of 
two additional risk factors qualified for enrolment. 
previously treated patients should not have a com-
pelling indication to continue treatment and should 
be on a single drug. After a 4-week run-in period off 
treatment, eligible patients had a sitting blood pres-
sure ranging from 140 to 179 mmHg systolic or from 
90 to 109 mmHg diastolic, or both, while systolic 
blood pressure measured immediately after standing 
up had to be at least 110 mmHg. These blood pres-
sure thresholds were averages of three consecutive 
readings obtained by means of validated (20) omron 
705iT monitors (omron Healthcare Co., Ltd., 
Kyoto, Japan) fitted with a cuff adjusted to arm cir-
cumference. in addition to major illness and high 
cardiovascular risk, the exclusion criteria encom-
passed: atrial fibrillation, electrocardiographic left 
ventricular hypertrophy with strain pattern, a serum 
creatinine concentration, higher than 1.4 mg/dl in 
women or 1.5 mg/dl in men, and proteinuria or hae-
maturia on a dipstick urine test.
The Study Coordinating Centre (SCC) in Leu-
ven randomized eligible patients to a single-pill com-
bination of either 6.25 mg hydrochlorothiazide plus 
5 mg bisoprolol (older drugs) or valsartan 160 mg 
plus amlodipine 5 mg (newer drugs). To achieve 
blood pressure control, the dose of bisoprolol or 
amlodipine in the single-pill combination could be 
doubled to 10 mg. in the two treatment groups, if 
blood pressure remained uncontrolled, a-methyl-
dopa could be added to the study medication.
At randomization and at 8, 16 and 24 weeks of 
follow-up, investigators record standard 12-lead 
ECgs by means of the paperless Cardiax device. 
HRV was measured from 5-min ECg recordings, 
using the Cardiax software (version 3.50.2, interna-
tional medical Equipment Developing Co. Ltd., 
Budapest, Hungary). The Cardiax software com-
putes the power spectrum in the frequency domain 
by fast Fourier transform and by autoregressive 
modelling and provides the low-frequency (0.04–
0.15 Hz) and high-frequency (0.15–0.40 Hz) com-
ponents of HRV in milliseconds and the low- to 
high-frequency ratio. normalized units (nu) of low- 
and high-frequency powers were calculated as the 
low- and high-frequency powers divided by the differ-
ence (total power very low-frequency power) 100.
The SAS software (SAS institute, Cary, nC, 
USA), version 9.3, was used for database manage-
ment and statistical analysis. The normality of con-
tinuously distributed variables was evaluated by the 
Kolmogorov–Smirnov statistic. Skewness and kurto-
sis were computed as the third and fourth moments 
about the mean (Supplementary Figures 1 and 2, to 
be found online at http://informahealthcare.com/doi/ 
abs/10.3109/08037051.2013.836810). non-normally 
distributed variables were log-transformed. The 
main analysis included all randomized patients with 
at least one follow-up visit according to the inten-
tion-to-treat principle. The cohort analysis only 
included patients who had HRV measured at each 
scheduled visit. means were compared by Student’s 
t-test for paired or unpaired data as appropriate 
and proportions by the c2 statistic. A mixed model 
was applied to assess treatment effects on HRV 
with the baseline values and follow-up time as fixed 
effects and centre as random effect. in sensitivity 
analyses, models also included heart rate as a covari-
able. Statistical significance was a two-sided p-value 
of 0.05.
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Results
of 294 screened patients, 271 were enrolled in the 
run-in period and 183 were randomized: 89 and 94 
to old and new drugs, respectively (Figure 1). in the 
old and new drug groups, respectively, 57 and 67 
completed the 6-month follow-up, 10 and nine 
patients defected from follow-up for undocumented 
reasons, and 22 and 18 withdrew from the study 
(Figure 1). of the 89 and 94 patients randomized to 
old and new drugs, 72 and 84 had at least one mea-
surement of HRV after randomization and were 
included in the present analysis.
Table i shows there were no between-group dif-
ferences in the baseline characteristics among all 
analysed patients (p  0.06) as well as among those 
in the cohort analysis (p  0.09) with the exception 
of waist circumference (p  0.04) and diastolic blood 
pressure (p  0.015). The analysis included 83 
(53.2%) women and 105 (67.3%) treatment-naïve 
patients. Age ( SD) averaged 51.5  8.9 years, rang-
ing from 30.5 to 68.9 years. Blood pressure at ran-
domization was 156.2  11.5 mmHg systolic and 
92.3  10.1 mmHg diastolic. Total, low-frequency 
and high-frequency power averaged 4.29  0.37 log 
ms2, 43.6  18.1 nu, and 20.02  14.42 nu and the 
low-to-high-frequency ratio was 0.40  0.36 log. 
patients included or not included in the cohort anal-
ysis had similar baseline characteristics (p  0.09).
women compared with men had higher nor-
malized high-frequency power (22.2 vs 17.5 nu; 
p  0.041) and therefore lower low- to high-frequency 
ratio (0.33 vs 0.48; p  0.013). Log total power was 
inversely correlated with age (r  0.20; p  0.013). 
The correlations coefficients with heart rate 
were 0.15 (p  0.057) for log total power,  0.06 
(p  0.43) for normalized low-frequency power, 
 0.19 (p  0.016) for normalized high-frequency 
power and 0.14 (p  0.073) for the low- to high-
frequency ratio.
During follow-up, heart rate decreased by 9.5 
beats/min on old drugs, with no change in patients 
( 2.2 beats/min) on new drugs, resulting in a base-
line-adjusted between-group difference of 7.3 beats/
min (Table ii; Figure 2). on old drugs, log total power 
Figure 1. Flow diagram of patients. Logistical reasons included delayed replenishment of the local supply of study medications and internet 
or computer failures at local centres. HCTz, hydrochlorothiazide. HRV refers to patients, who had at least one measurement of heart rate 
variability after randomization. Cohort refers to patients with all scheduled visits available for analysis.
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decreased by  0.20 ms2 (p  0.0003), high-frequency 
power increased by 7.1 nu (p  0.0020) and the low- to 
high-frequency ratio on the log scale decreased by 0.15 
(p  0.0054), with no change in low-frequency power 
( 1.0 nu; p  0.70). The corresponding within-group 
changes in the new-drug group were all non-significant 
(p  0.22). As a result (Table ii), the baseline-adjusted 
between-group differences (new minus old drugs) 
amounted to 3.4%, 3.6 nu,  3.3 nu and 21.2% for 
total power, low- and high-frequency power, and the 
low- to high-frequency ratio, respectively. with adjust-
ment for heart rate, these between-group differences 
disappeared (p  0.22), except for the decreased low-
frequency power in the old-drug group ( 4.67 nu; 
p  0.02). Analyses additionally adjusted for sex and 
age, or confined to patients with HRV available at all 
visits, or based on autoregressive modelling (Supple-
mentary Tables i and ii; Supplementary Figure 3 
to be found http://informahealthcare.com/doi/abs/10. 
3109/08037051.2013.836810) were confirmatory.
Table i. Baseline characteristics by type of analysis and randomization group.
Characteristic  
Randomization
Type of analysis
All patients Cohort
old new old new
number (%) with characteristic
All patients in category 72 84 39 47
women 37 (51) 46 (55) 24 (62) 24 (51)
Smokers 5 (7) 1 (1) 1 (3) 0 (0)
Drinking alcohol 22 (31) 25 (30) 11 (28) 18 (38)
Treatment naïve 49 (68) 56 (67) 26 (67) 28 (60)
mean SD of characteristic
Age, years 51.7  8.2 51.4  9.5 52.7  7.6 50.9  9.1
Body mass index (kg/m2) 28.7  4.7 27.6  4.9 28.9  4.9 27.5  4.4
waist circumference (cm) 95.2  11.5 93.4  11.3 97.6  11.2 92.8  10.4
Sitting measurements of
Systolic pressure (mmHg) 155.9  10.4 156.5  12.5 157.3  11.1 153.2  11.1
Diastolic pressure (mmHg) 92.6  9.8 92.1  10.5 95.4  9.4 90.6  8.5
Heart rate (beats/min) 70.4  10.8 70.4  9.4 71.8  9.1 71.0  10.6
Heart rate variability measurements
Total power (log ms2) 4.29  0.35 4.28  0.38 4.32  0.34 4.25  0.34
(geometric mean) (19,561) (19,116) (21,111) (17,824)
Low-frequency power (nu) 41.8  19.8 45.2  16.5 41.9  20.9 48.6  15.6
High-frequency power (nu) 18.8  14.3 21.1  14.5 20.0  16.2 19.6  13.6
Low- to high-frequency ratio, log 0.41  0.37 0.39  0.35 0.41  0.42 0.46  0.33
(geometric mean) (2.59) (2.45) (2.56) (2.88)
 The overall analysis encompasses patients with at least one measurement of heart rate variability after 
randomization and the cohort analysis patients with all scheduled visits available for analysis. old and 
new refer to single-pill combinations of hydrochlorothiazide plus bisoprolol and valsartan plus amlodipine. 
measurements of blood pressure are averages of three consecutive readings in the sitting position. Heart 
rate variability was analysed using fast Fourier transform. Between-group differences in the baseline 
characteristics among all patients (p  0.06) and among those in the cohort analysis (p  0.09) were not 
significant with the exception of waist circumference (p  0.04) and diastolic blood pressure (p  0.015) 
in the cohort analysis.
Table ii. Changes in heart rate and heart rate variability by randomization group.
Characteristic old new Δ (Ci) p
number 72 84
Heart rate measurements
Heart rate (beats/min)  9.5  1.6‡  2.2  1.4 7.3 (5.6 to 9.4)  0.0001
Total power (log ms2)  0.20  0.06‡  0.06  0.05 0.13 (0.04 to 0.22) 0.0038
(percent)  4.7  1.29 3.4 (1.0 to 5.7)
Low-frequency power (nu)  1.0  2.7  0.4  2.2 3.6 ( 0.08 to 7.4) 0.057
High-frequency power (nu) 7.1  2.3† 2.4  2.0  3.3 ( 6.6 to  0.02) 0.050
Low- to high-frequency ratio  0.15  0.05†  0.06  0.05 0.08 (0.01 to 0.15) 0.040
(percent)  36.6  15.4 21.2 (2.7 to 39.8)
 The overall analysis encompasses patients with at least one measurement of heart rate variability after 
randomization. Heart rate variability was analysed using fast Fourier transform. within-group changes 
(follow-up minus baseline) are mean SE. Δ (Ci) refers to the baseline-adjusted differences 95% 
confidence interval) of the treatment effects (new minus old). p-values were computed using a mixed 
model. Significance of the within-group changes: *p  0.05; †p  0.01; ‡p  0.001.
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Discussion
in this randomized clinical trial conducted in native 
Black African patients, treatment with a single-pill 
combination containing hydrochlorothiazide plus 
bisoprolol, compared with the combination of valsar-
tan plus amlodipine reduced total and low-frequency 
power, increased high-frequency power and there-
fore decreased the low-to-high-frequency ratio. The 
between-group differences in total power, high-fre-
quency power and the high- to low-frequency ration 
disappeared when adjusted for the lower heart rate 
in patients receiving the beta-blocker bisoprolol. The 
key finding of our study was that independent of 
heart rate low-frequency power remained suppressed 
in patients randomized to the combination including 
bisoprolol.
Bisoprolol is a selective b1-adrenoceptor antago-
nist that does not have intrinsic sympathomimetic 
(partial agonist) or membrane stabilizing (local 
anaesthetic) activity (21). Bisoprolol does not have 
any clinically relevant effects on the pharmacokinet-
ics of hydrochlorothiazide or vice versa. Both b1- and 
b2-adrenoceptors coexist in the atria of the human 
heart and are dynamically regulated in response to 
various physiological and pathological stimuli (22). 
The dynamically regulated interplay between both 
receptor types in the control of heart rate might 
explain why the low-frequency component of HRV 
remained lower in the old-drug compared with the 
new-drug group even after adjustment for heart rate. 
The absence of a correlation of the low-frequency 
component with heart rate would also support 
this hypothesis. Alternatively, cardioselective beta-
blockers with lipophilic characteristics, such as biso-
prolol penetrate the brain and might have effects on 
sympathetic modulation, for instance by indirectly 
Figure 2. Total power (A), low-frequency power (B), high-frequency power (C) and low- to high-frequency ratio (D) at randomization 
and during follow-up in patients randomized to old drugs (n  72) or new drugs (n  84). Heart rate variability was analysed using fast 
Fourier transform. plotted values are means SE. The number of patients contributing to the means is given. p values denote the 
significance of the between-group differences derived from a mixed model. Significance of the between-group differences at individual 
visits: *p  0.05; †p  0.01; ‡p  0.001.Bl
oo
d 
Pr
es
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
 U
 L
eu
ve
n 
on
 0
9/
25
/1
3
Fo
r p
er
so
na
l u
se
 o
nl
y.
6 C. E. Osakwe et al. 
increasing vagal tone. This might also explain why 
the low-frequency component of HRV remained 
suppressed independent of heart rate.
women compared with men had higher normal-
ized high-frequency power and a lower low- to high-
frequency ratio). These observations are in keeping 
with population data collected in the framework of 
the European project on genes in Hypertension 
(EpogH). Among 858 participants (53.8% female), 
women compared with men had lower (p  0.001) 
relative power in the low-frequency range (41.5 vs 
48.8 nu) and lower mean low- to high-frequency 
ratio (0.06 vs 0.11, log), but higher relative power in 
the high-frequency range (47.4 vs 40.6 nu). in 
EpogH participants, high-frequency power 
decreased with age (r  0.43), whereas the low-
frequency power increased (r  0.32) (23). The small 
age range (30.5–68.9 years), selection of patients 
with hypertension and ethnic differences might 
explain the absence of these associations with age in 
our currents study.
Beta-blockers without intrinsic sympathomimetic 
activity, such as bisoprolol, decrease heart rate and 
cardiac output. Lower heart rate is associated with 
reduced HRV. The lesser decrease in systolic blood 
pressure on the old-drug combination (18) is prob-
ably the consequence of the beta–blocker-induced 
reduction of heart rate, which is responsible for a 
later return of the reflected waves in the central arter-
ies during systole and more pronounced systolic 
augmentation (24,25). Furthermore, under treat-
ment with inhibitors of the renin system, but not 
under treatment with beta–blockers, the structural 
arteriolar abnormalities associated with hypertension 
regress. The ensuing reduction of the reflection coef-
ficients likely reduces the amplitude of the backward 
pressure wave and promotes a decrease of systolic 
blood pressure and pulse pressure in the brachial 
artery (26). Further studies should elucidate whether 
in addition to higher blood pressure level on the 
older drugs, reduced HRV, as suggested by the 
Framingham results (6,7), might contribute to the 
worse outcome on combinations of older vs newer 
drugs (27).
our current results must be interpreted within 
the context of some potential limitations. First, we 
only derived measures of HRV from 5min ECg 
recordings. However, Kotecha and colleagues (15) 
reported that 5-min HRV can predict obstructive 
angiographic coronary disease. Second, low- and 
high-frequency powers are only approximate mea-
sures of sympathetic and parasympathetic tome, 
respectively. Third, our study was not designed to 
explore the mechanisms explaining why low-fre-
quency power was reduced on bisoprolol indepen-
dent of heart rate.
in conclusion, the present study was the first to 
assess HRV in Black hypertensive patients born and 
living in sub-Saharan Africa. independent of heart 
rate, a reduced low-frequency power was observed in 
hypertensive patients randomized to antihyperten-
sive drug treatment based on beta-blockade. This 
might be a harbinger of less reduction of cardiovas-
cular risk compared with the newer drugs.
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Supplementary Table i. Heart rate variability based on autoregressive modelling by type of analysis and 
randomization group.
Characteristic Randomization
Type of analysis
All patients Cohort
old new old new
number 72 84 39 47
Total power (log ms2) 3.94  0.33 3.96  0.42 3.97  0.31 3.93  0.34
(geometric mean) 8710 9120 9333 8511
Low-frequency power (nu) 42.5  18.3 43.8  15.5 45.5  19.4 46.6  13.9
High-frequency power (nu) 18.8  14.3 20.3  14.0 20.4  16.7 19.3  13.4
Low- to high-frequency ratio (log) 0.42  0.37 0.40  0.34 0.41  0.42 0.45  0.33
(geometric mean) 2.63 2.51 2.57 2.81
 The overall analysis encompasses patients with at least one measurement of heart rate variability after 
randomization and the cohort analysis patients with all scheduled visits available for analysis. old and 
new refer to single-pill combinations of hydrochlorothiazide plus bisoprolol and valsartan plus amlodipine. 
Values are mean SD. Between-group differences among all patients (p  0.50) and among those in the 
cohort analysis (p  0.32) were not significant.
Supplementary Table ii. Changes in heart rate and heart rate variability by type of analysis and randomization group.
Characteristic 
Randomization
Type of analysis
All patients Cohort
old new Δ (Ci) p old new Δ (Ci) p
number 72 84 39 47
Heart rate  
(beats/min)
 9.5  1.6‡  2.2  1.4 7.3 (5.6 to 9.4)  0.0001  10.1  1.8‡  2.4  1.9 7.3 (4.4 to 10.0)  0.0001
Total power  
(log ms2)
 0.16  0.05†  0.04  0.06 0.14 (0.05 to 0.23) 0.0029  0.11  0.07  0.01  0.06 0.07 ( 0.04 to 0.18) 0.22
(percent)  5.1  1.0 4.1 (1.5 to 6.7)  2.8  0.25 2.5 ( 1.4 to 6.5)
Low-frequency  
power (nu)
 2.6  2.6  0.44  2.1 3.5 (0.02 to 6.9) 0.050  3.3  3.5  3.2  2.6 3.7 ( 0.63 to 8.0) 0.09
High-frequency 
power (nu)
6.2  2.2† 2.3  1.9  2.7 ( 5.7 to 0.35) 0.085 4.6  3.2 3.0  2.5  2.3 ( 6.3 to 1.8) 0.28
Low- to high- 
frequency 
ratio
 0.16  0.06†  0.06  0.05 0.09 (0.02 to 0.16) 0.020  0.15  0.08  0.10  0.06 0.08 ( 0.01 to 0.18) 0.097
(percent)  38.1  14.5 23.6 (3.9 to 42.0)  36.6  22.2 14.4 ( 2.4 to 31.2)
 The overall analysis encompasses patients with at least one measurement of heart rate variability after randomization and the cohort 
analysis patients with all scheduled visits available for analysis. Heart rate variability was analyzed using autoregressive modelling. within-
group changes (follow-up minus baseline) are mean SE. Δ (Ci) refers to the baseline-adjusted differences 95% confidence interval) of 
the treatment effects (new minus old). p-values were computed using a mixed model. Significance of the within-group changes *p  0.05; 
†p  0.01; ‡p  0.001.
 Supplementary material for osakwe CE, et al., Heart rate variability on antihypertensive drugs in Black patients 
living in sub-Saharan Africa, Blood pressure, 2013; doi: 10.3109/08037051.2013.836810
2 
Supplementary Figure 1. Frequency distributions of total (A), low-frequency (B) and high-frequency (C) power and the low-to-high-
frequency ratio (D) at randomization, based on the fast Fourier transform. S and K are the coefficients of skewness and kurtosis. The 
p-value is for departure of the actually observed distribution (Kernel distribution; dotted line) from normality (full line).
Supplementary Figure 2. Frequency distributions of total (A), low-frequency (B) and high-frequency (C) power and the low-to-high-
frequency ratio (D) at randomization, based on the autoregressive modelling. S and K are the coefficients of skewness and kurtosis. The 
p-value is for departure of the actually observed distribution (Kernel distribution; dotted line) from normality (full line).
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Supplementary Figure 3. Total (A), low-frequency (B) and high-frequency (C) power and the low-to-high-frequency ratio (D) at 
randomization and during follow-up in patients randomized to old drugs (n  72) or new drugs (n  84). Heart rate variability was analyzed 
using autoregressive modelling. plotted values are mean SE. The number of patients contributing to the means is given. p-values denote 
the significance of the between-group differences derived from a mixed model. Significance of the between-group differences at individual 
visits: *p  0.05; †p  0.01; ‡p  0.001.
